60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
April 03, 2024 07:58 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
March 14, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 20, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
February 08, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
January 31, 2024 11:15 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals (Nasdaq: SXTP) closes $2.4 million public offering.
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
January 30, 2024 09:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
January 22, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
January 16, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) announced that it has regained compliance with Nasdaq minimum listing requirements.
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
December 26, 2023 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
November 15, 2023 07:29 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will meet with FDA to discuss its proposed Phase II study on the use of tafenoquine for babesiosis.